Latest Cbd Products News

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

Elixinol Wellness Limited (ASX – EXL) has launched a substantial options offer to placement investors and its lead manager, pending shareholder approval. The offer could reshape the company’s capital structure and potentially raise $4.4 million upon exercise.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.